retatrutide phase 2 trial results obesity VisualAbstract: reduces body weight by 17.5% in patients with Triple hormone receptor agonist retatrutide

Ozempic is FDA-approved for type 2 diabetes management, while Wegovy is FDA-approved for chronic weight management in adults with obesity or overweight

Effective laboratory management fosters an efficient, compliant culture

This distributes the financial burden while generating valuable quality data

And at the heart of that design is a thoughtful, evidence-based approach to the Orforglipron cycle length

Preclinical models of opioid use disorder (OUD) have also demonstrated that GLP-1RAs reduce self-administration and relapse behavior for opioids, including heroin, fentanyl, and oxycodone

January 2026: Now that the JPML has approved centralization of Wegovy and other GLP-1 NAION (vision loss) lawsuits, the Judge overseeing the litigation is likely preparing for the first stages of the MDL